Aspirin may reduce the risk of colorectal neoplasia at doses similar to those recommended for the prevention of cardiovascular disease. Thus, we aimed to address whether enhanced platelet activation, as assessed by the measurement of the urinary excretion of 11-dehydro-TXB 2 (a major enzymatic metabolite of TXB 2), occurs in patients with colorectal cancer. In 10 patients with colorectal cancer, the urinary excretion of 11-dehydro-TXB 2 was significantly higher than in 10 controls, matched for sex, age and cardiovascular risk factors [1001(205-5571) versus 409(113-984) pg/mg creatinine, respectively, median (range), P2 levels, or in vivo, as assessed by urinary 11-dehydro-TXB 2 excretion. In conclusion, enhanced platelet activation occurs in colorectal cancer patients. Permanent inactivation of platelet COX-1 by low-dose aspirin might restore anti-tumor reactivity.
|Number of pages||5|
|Journal||Prostaglandins, Leukotrienes and Essential Fatty Acids|
|Issue number||2 SPEC. ISS.|
|Publication status||Published - Feb 2005|
ASJC Scopus subject areas
- Clinical Biochemistry
- Endocrinology, Diabetes and Metabolism